MISSED OUT ON THE LATEST CLINICAL GUIDELINE ANNOUNCEMENTS?

No problem, we’ve got you covered! Here’s a list to all guidelines and FDA approvals that were published last month. 


CLINICAL GUIDELINES

ACMG

ASCO

AHA/ASA

AUA/ASTRO

ASTRO

AUA

AACE

ABM

APTA

CNS

SCAI

SHEA

SIS

SITC

SNMMI


EXCLUSIVE SOCIETY GUIDELINES AND MANY MORE!

Search, bookmark, add notes and create your personal clinical guideline library with your digital copy or one of our society and specialty subscription bundles.   


FDA APPROVALS

MAY 2, 2022       CUVRIOR
Treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine

MAY 4, 2022       VOQUENZA
Treatment of Helicobacter pylori (H. pylori) infection in adults

MAY 13, 2022     RADICAVA ORS
Treatment of amyotrophic lateral sclerosis (ALS)

MAY 13, 2022      MOUNJARO
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

MAY 19, 2022       IV TPOXX
Treatment of smallpox

MAY 24, 2022       VTAMA
Topical treatment of plaque psoriasis in adults

MAY 24, 2022       TYVASO DPI
Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability

MAY 25, 2022       DUPIXENT
To treat eosinophilic esophagitis patients 12 years and older

MAY 25, 2022       TIBSOVO
Treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy

MAY 27, 2022       KYMRIAH
Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy

MAY 27, 2022       OPDIVO
First-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status

MAY 27, 2022       FYLNETRA
Multiple indications as biosimilar

MAY 31, 2022       EVRYSDI
Label extension to include infants under 2 months old with spinal muscular atrophy (SMA)


Copyright © 2022 Guideline Central, All rights reserved.